SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 13.0% Stake in 10x Genomics, Inc.

FMR LLC and its control person, Abigail P. Johnson, have reported a continued beneficial ownership of 13.0% of 10x Genomics, Inc.'s Class A Common Stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 14,683,871.79 shares of 10x Genomics, Inc. Class A Common Stock.
• This ownership represents 13.0% of the outstanding Class A Common Stock of 10x Genomics, Inc.
• The beneficial ownership includes 4,870,733 shares of Class B Common Stock, which are convertible into Class A Common Stock on a 1:1 basis.
• These Class B shares constitute 34.6503% of the total outstanding Class B Common Stock.
• If all outstanding Class B Common Stock were converted to Class A, the reported beneficial ownership would represent 12.0063% of the total outstanding Class A Common Stock.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates continued significant investment by a major institutional holder, which is generally a neutral to slightly positive signal, suggesting confidence in the company without implying any immediate strategic changes or financial distress.

Positives

• Continued significant investment by a major institutional investor (FMR LLC) and its principal (Abigail P. Johnson) in 10x Genomics, Inc.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, which indicates stability in the ownership structure.

Risks

• Potential dilution of Class A Common Stock if all Class B shares are converted, although the filing provides the pro-forma percentage (12.0063%) assuming such conversion.

Future Outlook

NA

Management Comments

• FMR LLC and Abigail P. Johnson certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

NA

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like FMR LLC can be viewed positively, indicating long-term interest and stability in the shareholder base.

Key Dates

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, SEC Filing, Schedule 13G, Class A Common Stock, Class B Common Stock, Institutional Investor, Biotechnology, Life Sciences